Ambrosan 30 mg
Ambroxol hydrochloride 30 mg in 1 tablet
Expectorant and mucolytic agent (ATC code: R05CB06)
Secretolytic treatment of acute and chronic bronchopulmonary diseases that are associated with abnormal sputum secretion and mucus transport disturbances.
Ambroxol increases sputum secretion in the respiratory tract and normalizes mucous viscosity. It increases the formation of pulmonary surfactant and stimulates the cilia. This action leads to an improvement in mucous transport (mucociliary clearance). Increasing sputum secretion and mucociliary clearance facilitates expectoration and eases coughs. Ambroxol reduces bronchial hyperreactivity, increases IgA secretion in bronchial secretions, and has an antioxidant effect.
Posology and method of administration
- Adults and adolescents over 12 years of age: 1 tablet thrice daily.
Therapeutic effect may be enhanced by administering 2 tablets twice daily.
- Children 5–12 years of age: 0.5 tablet 2–3 times daily.
Tablets should be taken after meals and should be sufficiently washed down. The mucolytic effect of ambroxol is enhanced by intake of fluid.
The duration of treatment by Ambrosan30 mg is determined individually, depending on therapeutic indications and type of disease.
Hypersensitivity to active substance or any of the excipients of this product, acute ulceration of the gastrointestinal tract.
Concomitant administration with antitussive agents may result in dangerous secretion congestion. Ambroxol administered concomitantly with antibiotics (amoxicillin, cefuroxime and erythromycin) results in increased concentration of antibiotics in bronchopulmonary secretion and in sputum. This effect may be used for therapeutic purposes.
Ambrosan may cause nausea. In isolated cases, there may be vomiting, diarrhoea, dyspepsia, abdominal pain, rash or urticaria.
Special warnings and precautions for use
In patients with impaired renal function or severe hepatic damage, ambroxol may be administered only with extra caution. During pregnancy, general principles of drug administration should be followed; administration of ambroxol-containing medications is not recommended especially during the first trimester. As Ambroxol passes into the breast milk, administration of this medicinal product is not recommended during lactation. Serious skin reactions have been reported, such as erythema multiforme, Stevens-Johnson syndrome (SJS) / toxic epidermal necrolysis (TEN) and acute generalised exanthematous pustulosis (AGEP). If symptoms or signs of progressive skin rashes appear (sometimes in the form of blisters or mucosal lesions), it is necessary to immediately stop taking ambroxol-hydrochloride and seek medical assistance.
Contents of container
10, 20, 30, 60, 100 or 500 tablets
Package available in the Czech Republic
For more detailed product information, see the Summary of Product Characteristics.